Osman Kibar (Samumed, now Biosplice)
April 16, 2021 07:14 AM EDT
Financing

Os­man Kibar lays down his hand at Sa­mumed, step­ping away from CEO role as his once-her­ald­ed an­ti-ag­ing biotech re­brands

Nicole DeFeudis

Editor

Sa­mumed made quite the en­trance back in 2016, when it launched with some an­ti-ag­ing pro­grams and a whop­ping $12 bil­lion val­u­a­tion. That lev­el of fan­fare was nowhere to be found on Thurs­day, when the com­pa­ny added an­oth­er $120 mil­lion to its cof­fers and qui­et­ly changed its name to Bios­plice Ther­a­peu­tics.

Why the sud­den re­brand?

“We did that for ob­vi­ous rea­sons,” CFO and CBO Erich Hors­ley told End­points News. “The name Bios­plice echoes our sci­ence much more than Sa­mumed does.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ono Phar­ma­ceu­ti­cal ac­quires De­ci­phera for $2.4B af­ter biotech's Phase 3 win

Bris­tol My­ers buys in­to Reper­toire's au­toim­mune vac­cines, giv­ing new life to Flag­ship start­up

FDA ap­proves X4 Phar­ma­ceu­ti­cal­s' pill for ul­tra-rare im­mun­od­e­fi­cien­cy dis­ease

As­traZeneca, Dai­ichi Sankyo’s En­her­tu claims an­oth­er Phase 3 vic­to­ry in HER2-low breast can­cer

Lead drug from J&J and Ad­dex's 20-year col­lab­o­ra­tion flunks Phase 2 in epilep­sy

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times